Arcturus Therapeutics Holdings Inc ARCT

NAS: ARCT | ISIN: US03969T1097 26/04/2024

26,55 USD (+1,45%)

(+1,45%) 26/04/2024

Grafiek Arcturus Therapeutics Holdings Inc

Grafiek Arcturus Therapeutics Holdings Inc

1 dag1d 1,45%
1 week1w 2,19%
1 maand1m -17,37%
3 maanden3m -16,30%
6 maanden6m 38,07%
1 jaar1j -0,38%
5 jaar5j 282,56%

Arcturus Therapeutics Holdings Inc in het nieuws

Toon enkel gratis nieuws

5 februari 2024 · New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster · Persbericht

21 december 2023 · CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster · Persbericht

12 december 2022 · CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics · Persbericht

1 november 2022 · CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology · Persbericht

2 juni 2021 · Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal Therapeutics · Persbericht

Profiel Arcturus Therapeutics Holdings Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Werknemers: 184

Aandelen Arcturus Therapeutics Holdings Inc

Beurswaarde: 704,37 miljoen USD

Effecten: 26,92 miljoen

Winst per aandeel (12 maand): PLUS

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe